請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16576
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉振軒 | |
dc.contributor.author | Pei-Yi Chu | en |
dc.contributor.author | 朱旆億 | zh_TW |
dc.date.accessioned | 2021-06-07T18:21:39Z | - |
dc.date.copyright | 2012-01-17 | |
dc.date.issued | 2012 | |
dc.date.submitted | 2011-12-11 | |
dc.identifier.citation | 1. Akagi T, Kinoshita T, Shien T, Hojo T, Akashi-Tanaka S, and Murata Y. Clinical and pathological features of intracystic papillary carcinoma of the breast. Surg Today 39: 5-8, 2009.
2. Altenberg B, and Greulich KO. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84: 1014-1020, 2004. 3. Arza B, Felez J, Lopez-Alemany R, Miles LA, and Munoz-Canoves P. Identification of an epitope of alpha-enolase (a candidate plasminogen receptor) by phage display. Thromb Haemost 78: 1097-1103, 1997. 4. Barbareschi M, Pecciarini L, Cangi MG, Macri E, Rizzo A, Viale G, and Doglioni C. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25: 1054-1060, 2001. 5. Barkley CR, Ligibel JA, Wong JS, Lipsitz S, Smith BL, and Golshan M. Mucinous breast carcinoma: a large contemporary series. Am J Surg 196: 549-551, 2008. 6. Barsky SH, and Karlin NJ. Mechanisms of disease: breast tumor pathogenesis and the role of the myoepithelial cell. Nat Clin Pract Oncol 3: 138-151, 2006. 7. Beck JS. Observer variability in reporting of breast lesions. J Clin Pathol 38: 1358-1365, 1985. 8. Benjamin SA, Lee AC, and Saunders WJ. Classification and behavior of canine mammary epithelial neoplasms based on life-span observations in beagles. Vet Pathol 36: 423-436, 1999. 9. Bostock DE. The prognosis following the surgical excision of canine mammary neoplasms. Eur J Cancer 11: 389-396, 1975. 10. Briffod M, Hacene K, and Le Doussal V. Immunohistochemistry on cell blocks from fine-needle cytopunctures of primary breast carcinomas and lymph node metastases. Mod Pathol 13: 841-850, 2000. 11. Bruce SJ, Gardiner BB, Burke LJ, Gongora MM, Grimmond SM, and Perkins AC. Dynamic transcription programs during ES cell differentiation towards mesoderm in serum versus serum-freeBMP4 culture. BMC Genomics 8: 365, 2007. 12. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC, Chen CY, Chen KC, Yang TY, Chou TY, Wang WH, Whang-Peng J, and Shih NY. Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 12: 5746-5754, 2006. 13. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J, and Viens P. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 202: 265-273, 2004. 14. Choi BJ, Cho YG, Song JW, Kim CJ, Kim SY, Nam SW, Yoo NJ, Lee JY, and Park WS. Altered expression of the KLF4 in colorectal cancers. Pathol Res Pract 202: 585-589, 2006. 15. Chu PY, Hsu NC, Liao AT, Shih NY, Hou MF, and Liu CH. Overexpression of alpha-enolase correlates with poor survival in canine mammary carcinoma. BMC Vet Res 7: 62, 2011. 16. Chu PY, Hsu NC, Liao AT, Yeh KT, Hou MF, and Liu CH. Elevated Kruppel-like factor 4 transcription factor in canine mammary carcinoma. BMC Vet Res 7: 58, 2011. 17. Collins LC, Carlo VP, Hwang H, Barry TS, Gown AM, and Schnitt SJ. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol 30: 1002-1007, 2006. 18. Cornet R, and de Keizer N. Forty years of SNOMED: a literature review. BMC Med Inform Decis Mak 8 Suppl 1: S2, 2008. 19. Cotchin E. Mammary neoplasms of the bitch. J Comp Pathol 68: 1-22, 1958. 20. Dang DT, Pevsner J, and Yang VW. The biology of the mammalian Kruppel-like family of transcription factors. Int J Biochem Cell Biol 32: 1103-1121, 2000. 21. De Matos AJ, Lopes CC, Faustino AM, Carvalheira JG, Dos Santos MS, Rutteman GR, and Gartner Mde F. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study. Anticancer Res 26: 1821-1826, 2006. 22. de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Vassallo J, and Alvarenga M. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast. Breast J 14: 68-75, 2008. 23. Destexhe E, Lespagnard L, Degeyter M, Heymann R, and Coignoul F. Immunohistochemical identification of myoepithelial, epithelial, and connective tissue cells in canine mammary gland tumors. Vet Pathol 30: 146-154, 1993. 24. Devilee P, Tavassoli FA, Editorial, and Consensus C. Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, 2003. 25. Douglas-Jones A, Shah V, Morgan J, Dallimore N, and Rashid M. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63. Histopathology 47: 202-208, 2005. 26. Dudani AK, Cummings C, Hashemi S, and Ganz PR. Isolation of a novel 45 kDa plasminogen receptor from human endothelial cells. Thromb Res 69: 185-196, 1993. 27. Elston CW, and Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991. 28. el-Zimaity HM, Graham DY, al-Assi MT, Malaty H, Karttunen TJ, Graham DP, Huberman RM, and Genta RM. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 27: 35-41, 1996. 29. Ferguson HR. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract 15: 501-511, 1985. 30. Ferreira E, Gobbi H, Saraiva BS, and Cassali GD. Columnar cell lesions of the canine mammary gland: pathological features and immunophenotypic analysis. BMC Cancer 10: 61, 2010. 31. Fleischer S, Sharkey M, Mealey K, Ostrander EA, and Martinez M. Pharmacogenetic and metabolic differences between dog breeds: their impact on canine medicine and the use of the dog as a preclinical animal model. AAPS J 10: 110-119, 2008. 32. Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, and Ruppert JM. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 60: 6488-6495, 2000. 33. Foster KW, Ren S, Louro ID, Lobo-Ruppert SM, McKie-Bell P, Grizzle W, Hayes MR, Broker TR, Chow LT, and Ruppert JM. Oncogene expression cloning by retroviral transduction of adenovirus E1A-immortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. Cell Growth Differ 10: 423-434, 1999. 34. Fowler EH, Wilson GP, and Koestner A. Biologic behavior of canine mammary neoplasms based on a histogenetic classification. Vet Pathol 11: 212-229, 1974. 35. Fritz AG. International classification of diseases for oncology : ICD-O. World Health Organization, Geneva, 2000. 36. Gama A, Alves A, and Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Archiv 453: 123-132, 2008. 37. Gama A, Alves A, Gartner F, and Schmitt F. p63: a novel myoepithelial cell marker in canine mammary tissues. Vet Pathol 40: 412-420, 2003. 38. Gamlem H, Nordstoga K, and Glattre E. Canine neoplasia--introductory paper. APMIS Suppl 5-18, 2008. 39. Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T, and Oka M. Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol 33: 725-731, 2008. 40. He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, Shima Y, Yamadori T, Suzuki H, Hirashima T, Matsui K, Shiono H, Okumura M, Nishida T, Tachibana I, Norioka N, Norioka S, and Kawase I. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci 98: 1234-1240, 2007. 41. Hennipman A, van Oirschot BA, Smits J, Rijksen G, and Staal GE. Glycolytic enzyme activities in breast cancer metastases. Tumour Biol 9: 241-248, 1988. 42. Hill CB, and Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol 123: 36-44, 2005. 43. Hsu WL, Huang HM, Liao JW, Wong ML, and Chang SC. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. Vet J 180: 116-123, 2009. 44. Huang CC, Liu Z, Li X, Bailey SK, Nail CD, Foster KW, Frost AR, Ruppert JM, and Lobo-Ruppert SM. KLF4 and PCNA identify stages of tumor initiation in a conditional model of cutaneous squamous epithelial neoplasia. Cancer Biol Ther 4: 1401-1408, 2005. 45. Javid SH, Smith BL, Mayer E, Bellon J, Murphy CD, Lipsitz S, and Golshan M. Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg 2008. 46. Jiang BH, Agani F, Passaniti A, and Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57: 5328-5335, 1997. 47. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, and Dessiris A. Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol 133: 246-252, 2005. 48. Karlsson EK, and Lindblad-Toh K. Leader of the pack: gene mapping in dogs and other model organisms. Nat Rev Genet 9: 713-725, 2008. 49. Kumaraguruparan R, Karunagaran D, Balachandran C, Manohar BM, and Nagini S. Of humans and canines: a comparative evaluation of heat shock and apoptosis-associated proteins in mammary tumors. Clin Chim Acta 365: 168-176, 2006. 50. Lerwill MF. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 28: 1076-1091, 2004. 51. Li J, Martinka M, and Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 29: 1373-1379, 2008. 52. Little NA, and Jochemsen AG. p63. Int J Biochem Cell Biol 34: 6-9, 2002. 53. Longacre TA, Ennis M, Quenneville LA, Bane AL, Bleiweiss IJ, Carter BA, Catelano E, Hendrickson MR, Hibshoosh H, Layfield LJ, Memeo L, Wu H, and O'Malley F P. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 19: 195-207, 2006. 54. Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, Maisonneuve P, Vento AR, and Viale G. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 101: 349-353, 2007. 55. Martin PM, Cotard M, Mialot JP, Andre F, and Raynaud JP. Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate. Cancer Chemother Pharmacol 12: 13-17, 1984. 56. Matos I, Dufloth R, Alvarenga M, Zeferino LC, and Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 447: 688-694, 2005. 57. McConnell BB, and Yang VW. Mammalian Kruppel-like factors in health and diseases. Physiol Rev 90: 1337-1381, 2010. 58. Meuten DJ. Tumors in domestic animals. Iowa State Press, Ames, Iowa, 2002. 59. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, and Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 30: 1682-1691, 1991. 60. Misdorp W, Armed Forces Institute of P, American Registry of P, and Oncology WHOCCfWRoC. Histological classification of mammary tumors of the dog and the cat. Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, Washington, D.C., 1999. 61. Misdorp W, Else RW, Hellmén E, and Lipscomb TP. Histological Classification of Mammary Tumors of the Dog and Cat. American Registry of Pathology, Washington, D. C., 1999. 62. Misdrop W, Else RW, Hellmen E, and Lipscomb TP. Histological classification of mammary tumors of the dog and the cat. In: World Health Organization International Histological Classification of Tumors of Domestic Animals, 2nd Edit, Armed Forces Institute of Pathology, Washington DC, 1-59, 1999. 63. Misforp W, Else RW, Hellmen E, and Lipscomb TP. Histological Classification of Mammary Tumors of the Dog and the Cat. Armed Forces Washington DC, Institute of Pathology, 1999. 64. Monlux AW, Roszel JF, MacVean DW, and Palmer TW. Classification of epithelial canine mammary gland tumors in a defined population. Vet Pathol 14: 194-217, 1977. 65. Moriya T, Kasajima A, Ishida K, Kariya Y, Akahira J, Endoh M, Watanabe M, and Sasano H. New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med Mol Morphol 39: 8-13, 2006. 66. Moriya T, Kozuka Y, Kanomata N, Tse GM, and Tan PH. The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology 41: 68-76, 2009. 67. Moulton JE, Taylor DO, Dorn CR, and Andersen AC. Canine mammary gland tumors. Pathol Vet 7: 289-320, 1970. 68. Mouser P, Miller MA, Antuofermo E, Badve SS, and Mohammed SI. Prevalence and classification of spontaneous mammary intraepithelial lesions in dogs without clinical mammary disease. Vet Pathol 47: 275-284, 2010. 69. Murali R, Hughes MT, Fitzgerald P, Thompson JF, and Scolyer RA. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma. Ann Surg 249: 641-647, 2009. 70. Nakajima K, Hamanoue M, Takemoto N, Hattori T, Kato K, and Kohsaka S. Plasminogen binds specifically to alpha-enolase on rat neuronal plasma membrane. J Neurochem 63: 2048-2057, 1994. 71. Naumann CM, Alkatout I, Hamann MF, Al-Najar A, Hegele A, Korda JB, Bolenz C, Kloppel G, Junemann KP, and van der Horst C. Interobserver variation in grading and staging of squamous cell carcinoma of the penis in relation to the clinical outcome. BJU Int 2009. 72. Nerurkar VR, Chitale AR, Jalnapurkar BV, Naik SN, and Lalitha VS. Comparative pathology of canine mammary tumours. J Comp Pathol 101: 389-397, 1989. 73. Ostrander EA, and Wayne RK. The canine genome. Genome Res 15: 1706-1716, 2005. 74. Ottesen GL. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. APMIS Suppl 1-67, 2003. 75. Owen LN. The TNM Classification of Tumors in Domestic Animals. World Health Organization, Geneva, 1980. 76. Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cell Mol Life Sci 58: 902-920, 2001. 77. Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, Bland KI, LoBuglio AF, Lobo-Ruppert SM, and Ruppert JM. Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res 10: 2709-2719, 2004. 78. Paoloni M, and Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156, 2008. 79. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, and Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146, 2008. 80. Parkin DM, Bray F, Ferlay J, and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001. 81. Peebles KA, Duncan MW, Ruch RJ, and Malkinson AM. Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity has been abrogated by transfection with the gap junction structural gene for connexin 43, Gja1. Carcinogenesis 24: 651-657, 2003. 82. Perez Alenza MD, Pena L, del Castillo N, and Nieto AI. Factors influencing the incidence and prognosis of canine mammary tumours. J Small Anim Pract 41: 287-291, 2000. 83. Polyak K, and Hu M. Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia 10: 231-247, 2005. 84. Porrello A, Cardelli P, and Spugnini EP. Oncology of companion animals as a model for humans. an overview of tumor histotypes. J Exp Clin Cancer Res 25: 97-105, 2006. 85. Prier JE, and Brodey RS. Canine Neoplasia. A Prototype for Human Cancer Study. Bull World Health Organ 29: 331-344, 1963. 86. Racz A, Brass N, Hofer M, Sybrecht GW, Remberger K, and Meese EU. Gene amplification at chromosome 1pter-p33 including the genes PAX7 and ENO1 in squamous cell lung carcinoma. Int J Oncol 17: 67-73, 2000. 87. Rakovitch E, Mihai A, Pignol JP, Hanna W, Kwinter J, Chartier C, Ackerman I, Kim J, Pritchard K, and Paszat L. Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ ? Breast Cancer Res Treat 87: 265-272, 2004. 88. Ramalho LN, Ribeiro-Silva A, Cassali GD, and Zucoloto S. The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms. Vet Pathol 43: 424-429, 2006. 89. Redlitz A, Fowler BJ, Plow EF, and Miles LA. The role of an enolase-related molecule in plasminogen binding to cells. Eur J Biochem 227: 407-415, 1995. 90. Richards HG, McNeil PE, Thompson H, and Reid SW. An epidemiological analysis of a canine-biopsies database compiled by a diagnostic histopathology service. Prev Vet Med 51: 125-136, 2001. 91. Sarli G, Preziosi R, Benazzi C, Castellani G, and Marcato PS. Prognostic value of histologic stage and proliferative activity in canine malignant mammary tumors. J Vet Diagn Invest 14: 25-34, 2002. 92. Schnitt SJ. The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin. Breast Cancer Res 11: 101, 2009. 93. Segre JA, Bauer C, and Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nat Genet 22: 356-360, 1999. 94. Shah VI, Flowers CI, Douglas-Jones AG, Dallimore NS, and Rashid M. Immunohistochemistry increases the accuracy of diagnosis of benign papillary lesions in breast core needle biopsy specimens. Histopathology 48: 683-691, 2006. 95. Shi P, Wang M, Zhang Q, and Sun J. Lipid-rich carcinoma of the breast. A clinicopathological study of 49 cases. Tumori 94: 342-346, 2008. 96. Shields JM, Christy RJ, and Yang VW. Identification and characterization of a gene encoding a gut-enriched Kruppel-like factor expressed during growth arrest. J Biol Chem 271: 20009-20017, 1996. 97. Shizawa S, Sasano H, Suzuki T, Ishii H, Takeda T, and Nagura H. Low-grade adenosquamous carcinoma of the breast: a case report with cytologic findings and review of the literature. Pathol Int 47: 264-267, 1997. 98. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, and Loda M. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157: 1769-1775, 2000. 99. Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, Bussolati G, Coleman D, Connolly CE, Eusebi V, De Miguel C, Dervan P, Drijkoningen R, Elston CW, Faverly D, Gad A, Jacquemier J, Lacerda M, Martinez-Penuela J, Munt C, Peterse JL, Rank F, Sylvan M, Tsakraklides V, and Zafrani B. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 434: 3-10, 1999. 100. Spugnini EP, Dotsinsky I, Mudrov N, Cardosi G, Citro G, D'Avino A, and Baldi A. Biphasic pulses enhance bleomycin efficacy in a spontaneous canine perianal tumors model. J Exp Clin Cancer Res 26: 483-487, 2007. 101. Strandberg JD, and Goodman DG. Animal model of human disease: canine mammary neoplasia. Am J Pathol 75: 225-228, 1974. 102. Sutter NB, and Ostrander EA. Dog star rising: the canine genetic system. Nat Rev Genet 5: 900-910, 2004. 103. Takahashi K, and Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676, 2006. 104. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872, 2007. 105. Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, and Nakamura K. Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics 5: 1686-1692, 2005. 106. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, Green M, Cozen W, Cockburn M, Sibug Saber M, Topor M, Zeruto C, Abedi-Ardekani B, Reichman ME, and Hewitt SM. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 69: 2950-2955, 2009. 107. Tan PH, Tse GM, and Bay BH. Mucinous breast lesions: diagnostic challenges. J Clin Pathol 61: 11-19, 2008. 108. Thomas R, Duke SE, Karlsson EK, Evans A, Ellis P, Lindblad-Toh K, Langford CF, and Breen M. A genome assembly-integrated dog 1 Mb BAC microarray: a cytogenetic resource for canine cancer studies and comparative genomic analysis. Cytogenet Genome Res 122: 110-121, 2008. 109. Tiseo M, Ardizzoni A, Cafferata MA, Loprevite M, Chiaramondia M, Filiberti R, Marroni P, Grossi F, and Paganuzzi M. Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer. Anticancer Res 28: 507-513, 2008. 110. Troxell ML, Masek M, and Sibley RK. Immunohistochemical staining of papillary breast lesions. Appl Immunohistochem Mol Morphol 15: 145-153, 2007. 111. Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, and Wu LW. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 46: 1712-1723, 2010. 112. Tse GM, Tan PH, and Moriya T. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 62: 407-413, 2009. 113. Tse GM, Tan PH, Lui PC, Gilks CB, Poon CS, Ma TK, Law BK, and Lam WW. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 60: 315-320, 2007. 114. Tse GM, Tan PH, Putti TC, Lui PC, Chaiwun B, and Law BK. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol 59: 1079-1083, 2006. 115. Tu SH, Chang CC, Chen CS, Tam KW, Wang YJ, Lee CH, Lin HW, Cheng TC, Huang CS, Chu JS, Shih NY, Chen LC, Leu SJ, Ho YS, and Wu CH. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat 121: 539-553, 2010. 116. Turner J, and Crossley M. Mammalian Kruppel-like transcription factors: more than just a pretty finger. Trends Biochem Sci 24: 236-240, 1999. 117. Verghese ET, den Bakker MA, Campbell A, Hussein A, Nicholson AG, Rice A, Corrin B, Rassl D, Langman G, Monaghan H, Gosney J, Seet J, Kerr K, Suvarna SK, Burke M, Bishop P, Pomplun S, Willemsen S, and Addis B. Interobserver variation in the classification of thymic tumours--a multicentre study using the WHO classification system. Histopathology 53: 218-223, 2008. 118. Viera AJ, and Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 37: 360-363, 2005. 119. Vinothini G, Balachandran C, and Nagini S. Evaluation of molecular markers in canine mammary gland tumors: correlation with histological grading. Oncol Res 18: 193-201, 2009. 120. Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC, Wu TT, Huang S, and Xie K. Drastic down-regulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res 65: 2746-2754, 2005. 121. Werling RW, Hwang H, Yaziji H, and Gown AM. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 27: 82-90, 2003. 122. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, and Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448: 318-324, 2007. 123. Williams-Fritze MJ, Carlson Scholz JA, Bossuyt V, and Booth CJ. Use of p63, a myoepithelial cell marker, in determining the invasiveness of spontaneous mammary neoplasia in a rhesus macaque (Macaca mulatta). J Am Assoc Lab Anim Sci 50: 252-257, 2011. 124. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, and Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145, 2007. 125. World Health O. ICD 10 checklists. 1996. 126. Wu W, Tang X, Hu W, Lotan R, Hong WK, and Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 19: 319-326, 2002. 127. Wygrecka M, Marsh LM, Morty RE, Henneke I, Guenther A, Lohmeyer J, Markart P, and Preissner KT. Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood 113: 5588-5598, 2009. 128. Yamagami T, Kobayashi T, Takahashi K, and Sugiyama M. Prognosis for canine malignant mammary tumors based on TNM and histologic classification. J Vet Med Sci 58: 1079-1083, 1996. 129. Yang A, and McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol 1: 199-207, 2000. 130. Yeh IT, and Mies C. Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med 132: 349-358, 2008. 131. Yet SF, McA'Nulty MM, Folta SC, Yen HW, Yoshizumi M, Hsieh CM, Layne MD, Chin MT, Wang H, Perrella MA, Jain MK, and Lee ME. Human EZF, a Kruppel-like zinc finger protein, is expressed in vascular endothelial cells and contains transcriptional activation and repression domains. J Biol Chem 273: 1026-1031, 1998. 132. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H, and Ai W. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 30: 2161-2172, 2011. 133. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II, and Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920, 2007. 134. Zaidan Dagli ML. The search for suitable prognostic markers for canine mammary gland tumors: A promising outlook. Vet J 177: 3-5, 2008. 135. Zhang L, Cilley RE, and Chinoy MR. Suppression subtractive hybridization to identify gene expressions in variant and classic small cell lung cancer cell lines. J Surg Res 93: 108-119, 2000. 136. Zhang P, Andrianakos R, Yang Y, Liu C, and Lu W. Kruppel-like factor 4 (Klf4) prevents embryonic stem (ES) cell differentiation by regulating Nanog gene expression. J Biol Chem 285: 9180-9189, 2010. 137. Zhang RR, Man YG, Vang R, Saenger JS, Barner R, Wheeler DT, Liang CY, Vinh TN, and Bratthauer GL. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res 5: R151-156, 2003 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16576 | - |
dc.description.abstract | 自然發生的犬乳房腫瘤已經被證實是一個研究人類乳癌相當合適的動物模型。本研究主要在探討犬乳房腫瘤預後不良的生物標記。第二章中,主要為比較犬和人的乳房腫瘤的分類系統。三位人醫病理醫師仔細比較WHO/AFIP腫瘤分類系統在犬和人乳房腫瘤的差異。在39個犬乳房腫瘤的分類中,共有22個(56.4%)的分類可以和人乳房腫瘤相通,因此可以證明犬和人乳房腫瘤在分類上有相當高的一致性。第三章中,共有136片犬乳房腫瘤的病理切片,分成兩組,分別由3位獸醫病理醫師和3位人醫病理醫師閱片。病理醫師間的一致性程度是用統計Kappa值(κ)來評估。在三位人醫病理醫師間,呈現中等到良好程度的一致性 (κ=0.68-0.81)。而在三位獸醫病理醫師間,一致性程度則較不理想(κ= -0.06 to 0.25)。第四章中,邀請10位訓練良好且相當有經驗的獸醫病理醫師各自參與相同的15個犬乳房腫瘤切片的病理閱片診斷。結果呈現中等程度的一致性(平均κ = 0.43)。故由第三章和第四章的研究顯示,診斷不一致的情況確實是存在,因此具有高正確性和高再現性之國際間皆可接受的犬乳房腫瘤病理診斷分類及定義是相當重要的。第五章中,肌上皮細胞標記,p63和calponin,在人類乳房腫瘤中,已被廣泛使用在日常病理診斷中,用來評估乳房腫瘤是否具有侵犯性。19例原先診斷為管狀乳突癌的犬之病理切片,用免疫組織化學染色法,研究p63和calponin的表現,9例的p63和calponin並未表現,故顯示有肌上皮細胞的缺少,且其中5例產生遠端轉移或因癌症死亡。臨床症狀初次表現到病理診斷確診時間和存活時間在9例缺少肌上皮細胞的犬中,皆明顯較短 (P值分別是0.001和0.021)。根據上述研究,管狀乳突癌在犬乳房腫瘤中,也許被過度診斷。在犬乳房的管狀乳突瘤的困難診斷病例,針對p63和calponin進行免疫組織化學染色是一個相當推薦的病理診斷輔助工具。第六章中,α-Enolase (ENO1)是一個重要的醣解酵素,在很多人類癌症的生發過程中,包括乳癌,扮演一定程度的角色。本研究中,收集82例犬乳房腫瘤,利用免疫組織化學染色法,來研究ENO1在犬乳房腫瘤中的表現,並以Quick score為免疫組織化學法染色結果的定量方法。ENO1的過度表現和較短的存活時間有關(P=0.019)。因此ENO1的過度表現可以用來當成是犬乳房癌症的一項預後不良的預後指標。第七章中,Krüppel-like factors (KLFs)是生物和生理系統的一群重要調節因子,它們在癌症的細胞增生、分化和存活所扮演的角色也被廣泛的研究。在這群KLFs中,KLF4在人類乳癌中是高度表現且被證實扮演一個致癌因子的角色。本研究中,收集142例犬乳房腫瘤,利用免疫組織化學染色法,來研究KLF4在犬乳房腫瘤中的表現,並以Quick score為免疫組織化學法染色結果的定量方法。KLF4的高表現和腫瘤細胞分化程度較差、癌症期別較晚、以及單純癌和複雜癌的亞型有關。Kaplan-Meier存活分析亦顯示具有高度細胞核表現KLF4的犬,其存活時間較低度/中度表現的犬為短 (P=0.011)。因此KLF4在犬乳癌中是高度表現的話,則是較為惡性的。 | zh_TW |
dc.description.abstract | Spontaneous occurring canine mammary gland tumors (MGTs) are proved to be a suitable animal model for tumor-related studies of human breast cancer. Biomarkers of poor prognosis were surveyed in the present study. In chapter II, comparisons of tumor classification systems between canine and human mammary tumors were conducted. WHO/AFIP tumor classification system for canine mammary gland tumors was thoroughly reviewed by three human pathologists blindly. Overall, 22 (56.4%) of canine tumor classification can fit into human breast tumor classification system and it showed a relatively high concordant rate between canine and human mammary tumor classification systems. In chapter III, one hundred and thirty-six selected canine MGTs with histological slides were divided into two groups and were randomly reviewed blindly by three veterinary pathologists and three human pathologists. Kappa (κ) statistics were calculated to evaluate the level of agreement. For three human pathologists involved in this study, a moderate to good level of agreement was present among their diagnosis (κ=0.68-0.81). However, three veterinary pathologists participated in this study showed only a low levels of agreement (κ= -0.06 to 0.25). In chapter IV, fifteen canine MGTs slides were coded and evaluated independently by ten well-trained and experienced veterinary pathologists. Overall, we found only moderate interobserver agreement among veterinary pathologists (mean kappa=0.43). We conclude that substantially high interobserver variations do exist among pathologists and internationally accepted pathological diagnostic definitions with high accuracy and reproducibility among pathologists are required. In chapter V, immunohistochemical stains for p63 and calponin, described as myoepithelial cell markers, are helpful in determining the invasiveness of human breast tumors. Nineteen canine cases with original diagnosis of tubulopapillary carcinoma were selected for study of p63 and calponin. Nine of the selected 19 cases revealed loss of myoepithelial cells by negative staining for p63 and calponin and five of them developed metastasis or tumor-related death. The time of initial presence of clinical symptoms to pathological diagnosis and the survival time were also statistically lesser in the 9 cases without the expression of p63 and calponin (p=0.001 and p=0.021, respectively). In conclusion, tubulopapillary carcinoma may be an over-diagnosed entity in canine MGTs. Immunohistochemical stains for p63 and calponin are recommended for difficult cases to determine the malignancy in canine mammary tubulopapillary tumors. In chapter VI, α-Enolase (ENO1) is a key glycolytic enzyme implicated in the development of many human cancers including breast cancer. Immunohistochemical staining was employed to investigate the expression of ENO1 in 82 cases of canine mammary tumor. Quantification of immunohistochemistry was carried out using Quick score. Overexpression of ENO1 correlated significantly with shorter cause-specific survival (P = 0.019). Our findings suggest that overexpression of ENO1 may be used as a prognostic marker for poor outcome in canine mammary carcinoma. In Chapter VII, Krüppel-like factors (KLFs) are critical regulators of biological and physiological systems and have been extensively studied for their roles in cell proliferation, differentiation and survival in the context of cancer. Among the KLFs, KLF4 is highly expressed in human breast cancers and plays an oncogenic role. Immunohistochemistry was employed to investigate the expression of KLF4 in 142 cases of canine MGTs. Quick score system was used for the immunohistochemical quantification of KLF4. High expression level of KLF4 expression was statistically associated with high grade, late stage, and histological subtypes of simple and complex carcinoma. The Kaplan-Meier survival analysis also indicated that dogs with high nuclear KLF4 expression had a significantly shorter cause-specific survival than those with low/moderate KLF4 expression (P = 0.011). KLF4 is highly and frequently expressed in canine mammary carcinoma and correlates with a more aggressive phenotype. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T18:21:39Z (GMT). No. of bitstreams: 1 ntu-101-D97629002-1.pdf: 1214635 bytes, checksum: ba8efee0a983d4281b8116281cf1184c (MD5) Previous issue date: 2012 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 iii 中文摘要 v 英文摘要 vii Chapter I General Introduction 1 Chapter II Comparative studies of tumor classification systems between canine and human mammary tumors 17 Chapter III Substantial interobserver variation among morphopathological diagnosis of canine mammary gland tumors from veterinary and human pathologists 45 Chapter IV Interobserver Variation in the Morphopathological Diagnosis of Canine Mammary Gland Tumors Among Veterinary Pathologists 65 Chapter V Tubulopapillary carcinoma – A frequent over-diagnosed entity in canine mammary gland tumors 77 Chapter VI Overexpression of α-enolase correlates with poor survival in canine mammary carcinoma 97 Chapter VII Elevated Krüppel-like factor 4 transcription factor in canine mammary carcinoma 123 Chapter VIII General Discussion, Conclusion and Perspectives 147 | |
dc.language.iso | en | |
dc.title | 犬乳房腫瘤預後因子之研究 | zh_TW |
dc.title | The Study of Prognostic Factors of Canine Mammary Gland Tumors | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 葉坤土,廖泰慶,李進成,龐飛 | |
dc.subject.keyword | 比較病理,犬,乳房腫瘤,腫瘤分類系統,免疫組織化學染色,預後因子, | zh_TW |
dc.subject.keyword | comparative pathology,canine,mammary gland tumor,tumor classification system,immunohistochemistry,prognostic factor, | en |
dc.relation.page | 157 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2011-12-12 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
顯示於系所單位: | 獸醫學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-101-1.pdf 目前未授權公開取用 | 1.19 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。